Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mol Neurobiol. 2019 Sep 13;57(1):150–158. doi: 10.1007/s12035-019-01765-9

Figure 2.

Figure 2.

CAMKII inhibition with tat-CN19o provides neuroprotection from CA/CPR induced Purkinje cell loss. A. Representative images of calbindin labeling used to quantify Purkinje cell density in the cerebellum at 7 days after CA/CPR. B. Quantification of Purkinje cell densities at 7 days after surgery. Mice that were subjected to CA/CPR and received tat-scr or 0.01 mg/kg tat-CN19o had lower cell densities. Tat-CN19o doses of 0.1 and 1.0 mg/kg had similar cell density to sham controls. N=4–8 per group. One-way ANOVA with Tukey multiple comparisons. * indicates p<0.05. ** indicates p<0.01.